MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock News
NASDAQ:MREO - Nasdaq - US5894921072 - ADR - Currency: USD
MREO Latest News, Press Relases and Analysis
Mereo BioPharma Provides Update on Lead Clinical Programs
Mereo BioPharma Provides Update on Lead Clinical Programs
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1...
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
LONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company...
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company...
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 ...
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical...
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3...
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company...
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company...
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company...
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical...
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and...
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical...